Anuh Pharma
80.52
+0.49(+0.61%)
Market Cap₹807.00 Cr
PE Ratio20.72
IndustryHealthcare
Company Performance:
1D+0.61%
1M+4.54%
6M-25.33%
1Y-26.70%
5Y-27.74%
View Company Insightsright
More news about Anuh Pharma
23May 25
Anuh Pharma Reports Mixed Q4 Results, Recommends Dividend
Anuh Pharma Ltd. released its Q4 FY2023-24 results, showing a 15.85% increase in revenue to ₹1,900 crore. However, net profit declined by 18.62% to ₹125 crore. The company's EBITDA margin contracted to 10.48%. Despite Q4 challenges, annual performance for FY2024 was strong with a 23.52% revenue growth and 66.02% increase in net profit. The board recommended a dividend of ₹1.50 per equity share.
Anuh Pharma
80.52
+0.49
(+0.61%)
1 Year Returns:-26.70%
Industry Peers
Sun Pharmaceutical
1,719.70
(-0.03%)
Divis Laboratories
6,392.50
(+0.50%)
Torrent Pharmaceuticals
3,850.00
(+0.73%)
Cipla
1,511.30
(+1.26%)
Dr Reddys Laboratories
1,271.40
(+0.44%)
Lupin
2,109.50
(+1.40%)
Zydus Life Science
914.35
(+1.43%)
Mankind Pharma
2,196.50
(+2.04%)
Aurobindo Pharma
1,183.00
(-0.28%)
Alkem Laboratories
5,506.50
(+0.69%)